Literature DB >> 29625664

Challenges in the treatment of asthma in children and adolescents.

Stanley J Szefler1, Bradley Chipps2.   

Abstract

OBJECTIVE: Despite the availability of effective treatments, asthma control in children and adolescents remains inadequate and rates of health care use are high. This follow-up to a recent review (O'Byrne et al, Eur Respir J. 2017;50[3]) examines a number of challenges in current pediatric asthma management compared with that of an adult perspective and discusses possible alternative strategies that might improve pediatric asthma management and control. DATA SOURCES: The evidence base for this review is limited because, historically, much of the research has been performed in adults. STUDY SELECTIONS: Not applicable.
RESULTS: Pediatric asthma management is complicated by variability in asthma severity and control and difficulty in measuring pulmonary function and airway inflammation. Current challenges in pediatric asthma management include the recommended initial therapy treating only the symptoms rather than the underlying inflammation and switching to controller therapy only when asthma subsequently worsens.
CONCLUSION: Alternative strategies that might improve pediatric asthma management and control include replacement of short-acting β2-agonist relievers by an inhaled corticosteroid plus a fast-acting β2-agonist (short-acting β2-agonist or fast- and long-acting β2-agonist) combination at Global Initiative for Asthma step 1 or 2 to ensure that patients receive an inhaled corticosteroid whenever they feel the need for symptomatic relief. Such an approach could eliminate the problem of learned overuse or over-reliance on short-acting β2-agonist reliever medication and address the other challenges in current pediatric asthma management. Clinical studies in pediatric patients or large studies involving a proportion of pediatric patients are required to provide the supporting evidence needed to help advance such new approaches and improve asthma control from a pediatric perspective.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29625664     DOI: 10.1016/j.anai.2018.01.003

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

1.  Exercise training as an adjunctive therapy to montelukast in children with mild asthma: A randomized controlled trial.

Authors:  Yan-Feng Zhang; Lin-Dong Yang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

2.  Challenges and choices in the pharmacological treatment of non-severe pediatric asthma: A commentary for the practicing physician.

Authors:  Omer Kalayci; Hanan Abdelateef; César Fireth Pozo Beltrán; Zeinab A El-Sayed; René Maximiliano Gómez; Elham Hossny; Mário Morais-Almeida; Antonio Nieto; Wanda Phipatanakul; Paulo Pitrez; Gary Wk Wong; Paraskevi Xepapadaki; Nikolaos G Papadopoulos
Journal:  World Allergy Organ J       Date:  2019-10-03       Impact factor: 4.084

3.  Impact of asthma control on different age groups in five Latin American countries.

Authors:  Marcela Batan Alith; Mariana Rodrigues Gazzotti; Oliver Augusto Nascimento; José Roberto Jardim
Journal:  World Allergy Organ J       Date:  2020-04-01       Impact factor: 4.084

4.  Medication Errors in Adolescents Using Asthma Controller Medications.

Authors:  Henry Clark; Delesha Carpenter; Kathleen Walsh; Scott A Davis; Nacire Garcia; Betsy Sleath
Journal:  Glob Pediatr Health       Date:  2020-12-14

5.  TSLP bronchoalveolar lavage levels at baseline are linked to clinical disease severity and reduced lung function in children with asthma.

Authors:  Elizabeth Chorvinsky; Gustavo Nino; Kyle Salka; Susana Gaviria; Maria J Gutierrez; Dinesh K Pillai
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

6.  MiR-203a-3p regulates TGF-β1-induced epithelial-mesenchymal transition (EMT) in asthma by regulating Smad3 pathway through SIX1.

Authors:  Qi Fan; Yu Jian
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.